Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase I Clinical Study to Evaluate the Safety and Efficacy of RGB-5088 in Patients With Type 1 Diabetes Mellitus
Sponsor: Hangzhou Reprogenix Bioscience, Inc
Summary
This Phase I clinical trial is a single-center, single-arm, open-label study aimed at evaluating the safety and therapeutic efficacy of RGB-5088 islet cell transplantation in patients with Type 1 Diabetes Mellitus.
Official title: A Single-Center, Single-Arm, Open-Label Phase I Clinical Trial Evaluating the Safety and Efficacy of RGB-5088 Islet Cell Injection in the Treatment of Type 1 Diabetes Mellitus
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2025-02-17
Completion Date
2031-12-31
Last Updated
2025-09-15
Healthy Volunteers
No
Interventions
RGB-5088
Transplantation under the anterior rectus sheath
Locations (1)
Tianjin First Center Hospital
Tianjin, Tianjin Municipality, China